Reneo Pharma announces last patient last visit in pivotal STRIDE study; topline data expected Dec 2023

OnKure Therapeutics, Inc.

Last patient last visit completed in STRIDE study of mavodelpar for primary mitochondrial myopathies; topline data expected December 2023.
Over 85% of eligible patients enrolled in ongoing STRIDE AHEAD study.
Company to share data analysis with FDA in Q1 2024; NDA submission planned first half 2024.
STRIDE and STRIDE AHEAD studies to form basis of NDA submission to FDA and other regulators.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.